time is running out, page-127

Emotions must be managed, I couldn't agree more.

Which is why fear-driven posts, dressed up as analysis and gliding over the most critical issues are also to be treated with scepticism.

Pain of dilution? What about the pain of shorting? Shall we talk about that? Or the pain of manipulation? Or the pain of misleading reports?

All that pain is only theoretical if you don't sell. and the stock recovers and starts to fly, the indications are that it will for reasons that you refuse to understand....but thanks for the reminders. I'm sure you'll continue to keep them coming.

You cannot say that a comprehensive analysis of a biotech in a unique, game changing position can be taken just on nuts & bolts accountancy. It's not just boring - that emotion can be managed - but it's ill-conceived. That's a much more serious situation.

Now you're claiming that I said dilution is a good thing? No. I said we are comparitively in a better position than companies who are heavily diluted, plus you have to look at where we are in terms of product to market in this unique field.

You take what is said and smash it to the nth degree with reductionist accountancy and then say, look see? someone who thinks MSB is a good buy has got it wrong!

Start with a sound approach which is applied to biotechs that don't need to go through the same costly process as DRUGs, and takes into account paradigm-shifting technology and we will all be in front.

Until then I won't be jumping through the lit hoops you raise as supposedly a test of competency. They're lacking in context, reductionist and ill-conceived.
But I'm sure somebody is scared...